Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,405 Shares

Posted by Brenda Bartman on May 6th, 2026

Natera, Inc. (NASDAQ:NTRA – Get Free Report) insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider owned 142,295 shares of the company’s stock, valued at approximately $28,984,068.55. This represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

On Monday, April 27th, Solomon Moshkevich sold 2,182 shares of Natera stock. The stock was sold at an average price of $204.10, for a total transaction of $445,346.20.
On Wednesday, April 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $202.30, for a total transaction of $606,900.00.
On Tuesday, March 10th, Solomon Moshkevich sold 915 shares of Natera stock. The shares were sold at an average price of $204.13, for a total transaction of $186,778.95.
On Monday, March 2nd, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $199.85, for a total value of $599,550.00.

Natera Stock Down 2.3%

NASDAQ:NTRA opened at $206.77 on Wednesday. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36. The stock’s fifty day moving average is $201.91 and its two-hundred day moving average is $214.51. The stock has a market capitalization of $29.42 billion, a price-to-earnings ratio of -135.14 and a beta of 1.57.

Natera (NASDAQ:NTRA – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The firm had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. During the same quarter in the previous year, the business earned ($0.41) EPS. On average, sell-side analysts expect that Natera, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research reports. TD Cowen reiterated a “buy” rating on shares of Natera in a report on Wednesday, January 7th. Wall Street Zen upgraded Natera from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. William Blair started coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Morgan Stanley lowered their target price on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

View Our Latest Research Report on NTRA

Institutional Investors Weigh In On Natera

Several institutional investors have recently modified their holdings of NTRA. Reflection Asset Management acquired a new stake in Natera in the fourth quarter valued at $29,000. Palladiem LLC purchased a new position in shares of Natera in the 4th quarter valued at about $31,000. Horizon Investments LLC purchased a new position in shares of Natera in the 3rd quarter valued at about $32,000. International Assets Investment Management LLC raised its position in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust lifted its stake in Natera by 103.8% during the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Key Natera News

Here are the key news stories impacting Natera this week:

Neutral Sentiment: CEO Steven Leonard Chapman sold 902 shares (≈$185,956) under a pre-arranged Rule 10b5-1 plan to cover taxes on vested awards. This reduced his ownership by ~0.60%. SEC Form 4
Neutral Sentiment: Insider John Fesko sold 291 shares (≈$59,993) under a Rule 10b5-1 plan to cover tax withholding, a ~0.16% reduction in his stake. SEC Form 4
Neutral Sentiment: Insider Solomon Moshkevich sold 3,405 shares (≈$693,564) under a pre-arranged plan to cover taxes, reducing his holding by ~2.34%. SEC Form 4
Neutral Sentiment: CFO Michael Burkes Brophy executed two 10b5-1 sales (482 shares at ~$210.49 and 313 shares at ~$206.16) totaling ~795 shares (~$165,984) to cover tax withholdings, trimming his stake by under 1%. SEC Form 4

Natera Company Profile

(Get Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.